Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (TriComB)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04564898 |
|
Recruitment Status :
Recruiting
First Posted : September 25, 2020
Last Update Posted : March 9, 2023
|
Sponsor:
Gruppo Oncologico del Nord-Ovest
Information provided by (Responsible Party):
Gruppo Oncologico del Nord-Ovest
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | September 2023 |
| Estimated Study Completion Date : | March 2024 |